To the editor:
Ludwiczek et al1 reported that nifedipine and other dihydropyridine-class calcium-channel blockers can reverse iron overload by stimulating the activity of divalent metal-ion transporter-1 (DMT1)2,3 and consequently mobilizing tissue iron. Since their paper disagreed with our published data4,5 regarding the activities of the DMT1 isoforms (described previously4,–6 ), we undertook to resolve that issue and examine the effect of nifedipine on DMT1 in vitro.
We found that nifedipine did not affect 59Fe2+ transport (Figure 1A) nor 54Mn2+ transport (supplemental Figure 1, available on the Blood Web site; see the Supplemental Materials link at the top of the online article) in HEK293 cells transiently transfected with human DMT1 isoform 1A/−IRE. Doxycycline-induced expression of rodent 1A/+IRE and 2/−IRE isoforms stably transfected in HEK293 cells resulted in similar protein levels on immunoblot (Figure 1B) and, as before,4 no differences in their ability to transport Fe2+ (P = .67; Figure 1C) or Mn2+ (P = .32; supplemental Figure 2). Nifedipine had no effect on metal-ion transport in cells expressing these isoforms. Other investigators observed that photodegraded nifedipine (PDN) stimulated iron uptake into erythrocytes7,8 or epidermal keratinocytes.9 We found that PDN stimulated uptake of Fe2+, but not Mn2+, in cells with minimal DMT1 expression (TetR, EV, or uninduced cells), but not in cells in which DMT1 expression was induced.
Fe2+-evoked currents in Xenopus oocytes expressing human 1A/+IRE DMT1 were unaffected by nifedipine and only slightly inhibited by PDN (Figure 1D). Nifedipine did not affect transport of 55Fe2+ in these cells at pH 6.5 or 5.5 (Figure 1E-F). A second dihydropyridine-class blocker, nicardipine, as well as diltiazem and verapamil also were without effect (supplemental Figure 3). PDN abolished that fraction of iron-transport activity attributable to DMT1 (Figure 1F) but stimulated iron transport in control (noninjected) oocytes, up to 50-fold more than that in untreated oocytes after 60 minutes' preincubation (Figure 1G). Treatment with either nifedipine or PDN had no effect on 54Mn2+ transport in control oocytes or oocytes expressing DMT1 (supplemental Figure 3B). We observed higher transport activity in oocytes expressing the 1A/+IRE isoform compared with 2/+IRE (supplemental Figure 4), consistent with a previous study in which we had demonstrated that the activities of the 4 isoforms correlated with the levels of their expression at the oocyte plasma membrane.5 After normalization for expression levels, the 2 isoforms did not differ in their pH dependence over the pH range 5.5 to 8.5 (supplemental Figure 4A) nor in their relative abilities to transport a range of divalent metal ions (supplemental Figure 4B).
Therefore, nifedipine does not increase metal-ion transport in 3 heterologous expression systems with multiple DMT1 isoforms. Instead, our data support earlier proposals7,–9 that PDN is an iron-specific ionophore. The ionophore effect of PDN was independent of DMT1 because (1) it was less apparent when cells overexpressed DMT1 than when DMT1 levels were lower or minimal; and (2) PDN stimulated the uptake of Fe, but not of Mn, while both are DMT1 substrates. Whereas the study by Ludwiczek et al1 presents the interesting possibility of using nifedipine to increase iron excretion in iron-overload conditions, the mechanism by which nifedipine (or PDN) leads to such an increase remains unclear and does not involve DMT1.
The online version of this letter contains a data supplement.
This study was presented in part at Experimental Biology 2008, San Diego, CA, April 8, 2008.10
Authorship
Acknowledgments: The human 1A/−IRE DMT1 in pcDNA3.1 construct was graciously sent to us by Drs Nadia Hubert and Matthias W. Hentze. This study was supported by PHS grants R01 DK080047 (to B.M.) and R01 DK059794 (to L.M.G.) from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the Laura & Michael Garrick Fund, and the University of Cincinnati. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIDDK, the National Institutes of Health, or the US Environmental Protection Agency.
Contribution: B.M. designed research, performed research, analyzed data, performed statistical analysis, and wrote the paper; A.S. designed research, performed research, analyzed data, and performed statistical analysis; A.J.G. and J.D.S. performed research; L.Z. designed research, performed research, and analyzed data; S.G. designed research, performed research, analyzed data, and performed statistical analysis; L.M.G. designed research, performed research, analyzed data, and wrote the paper; and M.D.G. designed research, performed research, analyzed data, performed statistical analysis, and wrote the paper.
Conflict-of-interest disclosure: The authors declare no competing financial interests.
Correspondence: Bryan Mackenzie, Department of Molecular & Cellular Physiology, University of Cincinnati College of Medicine, PO Box 670576, Cincinnati, OH 45267; e-mail: bryan.mackenzie@uc.edu; or Michael D Garrick, Department of Biochemistry, State University of New York–Buffalo, 140 Farber Hall, Buffalo, NY 14214; email: mgarrick@buffalo.edu.
References
National Institutes of Health